Yes, regarding that last point, I would add only that this is good not only for devices and medication but for vaccine development. We've seen that during the pandemic. We're really dependent on the proper evaluation of vaccines by Health Canada. We need to move in a very efficient manner. To rely on other jurisdictions to speed up the process is something that I think was done in that situation, but it needs to be expanded probably to developments of other biomedicals, vaccines or for cancer, so that we don't reinvent the wheel every time.
Of course, there are always going to be some specific needs and country-centric jurisdictions, and things like that. The main scientific problems stay the same. You don't have to redo the whole thing every time, I guess.